Congrats! Arch CKD lead Drs. Justin Chun and Arch CSO Daniel Muruve @ucalgarymed.bsky.social on new findings that suggest distinct lipid signatures may act as pathological indicators in glomerular kidney disease, with potential diagnostic and mechanistic insight.

iopscience.iop.org/article/10.1...

Patient Dosing Begins in Promising Phase II LSALT Peptide Trial No drug-related adverse events have been assessed to date in Arch Biopartners’ Phase II trial of LSALT peptide for cardiac surgery–associated acute kidney injury (CS-AKI), and a blinded data review co...

📰 The Clinical Trial Vanguard article reporting on Arch Biopartners ongoing Phase II LSALT Trial, Clinical Trial Updates www.clinicaltrialvanguard.com/news/patient...

March 24, 2026, News Release. Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial

🚨 Arch announced @fraserhealth.ca has entered into a Clinical Trial Agreement with the Company to enable Royal Columbian Hospital to prepare for recruitment in the Phase II CS-AKI trial evaluating LSALT peptide.

📖 www.archbiopartners.com/investor-hub...

#AKI #CSAKI #NephSky

March 20, 2026 - News Release: Arch Biopartners Announces St. Michael’s Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide

🚨 Arch Biopartners: St. Michael’s Hospital (Unity Health Toronto) has commenced patient dosing in the Phase II CS-AKI trial of LSALT peptide.

🧪 News also provides ongoing Phase II clinical trials updates.

📖 Full release: www.archbiopartners.com/investor-hub...

#AKI #CSAKI #NephSky

Technically Oversold with Support Solid Patents & A Heavyweight Board: Is This Stock Set to Soar? Arch Biopartners Inc (ARCH:TSXV; ACHFF:OTCQB) is a therapeutic biotech company focused on developing novel, on-target drugs for acute kidney injury (AKI) and chronic kidney disease (CKD). The companys...

📰 Streetwise Reports featured Arch Biopartners in a contributed technical analyst opinion discussing the company’s kidney-focused pipeline and recent public disclosures.

🔗 Read the full report here: www.streetwisereports.com/article/2026...

#ArchNews #BiotechNews

🚨 New peer-reviewed publication in Inflammation Research identifies IL-32 as a lipid droplet-associated cytokine linked to tubular injury in DKD.

The findings strengthen the scientific foundation for Arch Biopartners’ CKD Platform targeting IL-32

📖 archbiopartners.com/investor-hub

#CKD #NephSky

News Release - January 16, 2026 - Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board

🚨 Arch Biopartners announced the appointment of Dr. Patrick Vink, M.D., M.B.A., as Chairman of the Board, effective January 15, 2026. Dr. Vink brings extensive experience in global pharmaceutical leadership and governance.

📖 Full release:
archbiopartners.com/investor-hub

#ArchBiopartners #ArchNews

Boehringer spells out a $448M future for Rectify's ABC kidney disease program Boehringer Ingelheim has opened another front in its attack on chronic kidney disease (CKD),

🚨 Boehringer Ingelheim and Rectify Pharma outlined a $448M deal for a preclinical CKD program.

www.fiercebiotech.com/biotech/boeh...

Arch is advancing a CKD platform targeting IL-32.

🔬 archbiopartners.com/our-science

#Biotech #CKD

December 16 2025, News Release: Arch Biopartners Announces Ethics Approval for St. Michael’s Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide

🚨 Arch Biopartners announced that St. Michael’s Hospital @unityhealthto.bsky.social received ethics approval to join the Phase II CS-AKI trial evaluating LSALT peptide.

🏥 4th Canadian site, 9th globally.

🔗 Read more (and share): www.archbiopartners.com/arch-biopart...

#LSALTpeptide #AKI #CSAKI

Predicting pediatric cardiac surgery-associated acute kidney injury using machine learning - Pediatric Nephrology Background Prediction of cardiac surgery-associated acute kidney injury (CS-AKI) in pediatric patients is crucial to improve outcomes and guide clinical decision-making. This study aimed to develop a ...

🔎 A Pediatric Nephrology study (@ped-neph.bsky.social link.springer.com/article/10.1007/s00467-023-06197-1) shows machine learning can help predict AKI in children after heart surgery. Arch’s trials are evaluating drugs to prevent AKI in high-risk patients.

🔬 archbiopartners.com/our-science

#CSAKI

Outcomes of KDIGO-Defined CKD in U.S. Veterans With HFpEF, HFmrEF, and HFrEF:

📚 JACC: Heart Failure (www.jacc.org/doi/10.1016/j.jchf.2024.11.007): CKD in U.S. veterans with heart failure raised hospitalization and death risk across all ejection fractions. Underscores need for targeted CKD therapies.

🔬 archbiopartners.com/our-science/ckd-platform

#CKD #KidneyCare #NephSky

National CKD Framework This Framework will be Canada’s first comprehensive, evidence-based roadmap designed to transform kidney health outcomes across the country - and one that governments can use to inform policy, plannin...

📈 As CKD cases continue to rise in Canada, The Kidney Foundation is calling for a National CKD Framework at kidney.ca/Get-Involved/Advocacy/National-CKD-Framework

Arch is advancing CKD therapeutics developed in Calgary.

🔬 archbiopartners.com/our-science/ckd-platform

#CKD #KidneyCare #NephSky

CTV National News: More Canadians living with chronic kidney disease New data reveals chronic kidney disease is claiming the lives of more Canadians than ever before. Kathy Le on the health crisis.

📈 GBD study @thelancet.com, CKD in top 10 causes of death. @ctvnewscalgary.bsky.social reports cases have doubled in Canada www.ctvnews.ca/video/2025/12/01/ctv-national-news-more-canadians-living-with-chronic-kidney-disease/

🔬 archbiopartners.com/our-science/ckd-platform

#CKD #KidneyCare #NephSky

🧬 2023 Antioxidants review www.mdpi.com/2076-3921/12... links oxidative stress to AKI, CKD, and cardiovascular risk.

Arch is advancing Phase II trials targeting inflammation and injury before kidney damage is irreversible.

🔬 archbiopartners.com/our-science/lsaltpeptide

#AKI #KidneyCare #NephSky

Hemolysis Index and Cardiopulmonary Bypass Time as Predictors of Cardiac Surgery-associated Acute Kidney Injury: An Observational Cohort Study Acute kidney injury (AKI) is a common and serious complication of cardiac surgery, often linked to the use and duration of cardiopulmonary bypass (CPB). The Hemolysis Index (HI) has been proposed as a...

📚 Nov 2025 study in JCVA jcvaonline.com/article/S1053-0770(25)00632-9/fulltext In >1,000 cardiac surgery patients, elevated hemolysis index, and longer bypass time predicted AKI. Supports inflammation-targeted CS-AKI therapies.

🔬 archbiopartners.com/our-science/lsaltpeptide/

#CSAKI #LSALTpeptide

KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease This article is published as part of a supplement supported by Kidney Disease: Improving Global Outcomes (KDIGO). The development and publication of this guideline were supported by KDIGO. The opinion...

📚 KDIGO 2022 guideline - @theisn.org - www.kidney-international.org/article/S008... Managing diabetic CKD is complex and current treatments rely on broad effects.

On-target approaches are needed.
🔬 archbiopartners.com/our-science/ckd-platform

#CKD #KidneyCare #NephSky

Epidemiology of chronic kidney disease: an update 2022 Chronic kidney disease is a progressive condition that affects >10% of the general population worldwide, amounting to >800 million individuals. Chronic kidney disease is more prevalent in older indivi...

📚 A 2022 Kidney International Supplement @theisn.org - www.kisupplements.org/article/S215... shows rising CKD rates and gaps in diagnosis and treatment. More precise, pathway-focused therapies are needed.

🔬 archbiopartners.com/our-science/ckd-platform/

#CKD #KidneyCare #NephSky

Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023 CKD is a major global health issue, with rising prevalence and increasing importance as a cause of death and as a risk factor for cardiovascular death. A better understating of aetiology, appropriate ...

📚 @thelancet.com study - www.thelancet.com/journals/lan... - confirms CKD has entered the top 10 causes of death worldwide.

Arch is advancing IL-32–targeting drug candidates to address chronic kidney disease at the source.

🔬 archbiopartners.com/our-science/ckd-platform

#CKD #KidneyCare #NephSky

Models of sepsis-induced acute kidney injury Sepsis-induced acute kidney injury (S-AKI) is one of the most serious life-threatening complications of sepsis. The pathogenesis of S-AKI is complex a…

🧪 A Life Sciences review (www.sciencedirect.com/science/arti...) confirms that inflammation, vascular injury, and mitochondrial damage drive S-AKI.

These same mechanisms are also active in cardiac surgery-associated AKI (CS-AKI).

🔬 archbiopartners.com/our‑science/lsaltpeptide

#AKI #CSAKI #NephSky

CKD progression, kidney failure, and mortality among US patients with IgA nephropathy ABSTRACTBackground and Hypothesis. We assessed disease progression among patients with immunoglobulin A nephropathy (IgAN) and characterized factors associ

📈 A 2025 study in NDT (doi.org/10.1093/ndt/gfaf084) found high kidney failure & mortality rates in IgA nephropathy.

Arch’s CKD platform targets IL-32, a cytokine linked to kidney inflammation, complementing its AKI platform.
🔬 archbiopartners.com/our-science/ckd-platform/

#CKD #KidneyCare #NephSky

Acute Kidney Injury: A Blocked Diagnosis Acute kidney injury (AKI) is a common medical condition that we encounter in our daily clinical practice. However, in certain cases, ascertaining the underlying cause of the AKI could be challenging a...

📚 An AKI case in @cureusmedical.bsky.social (doi.org/10.7759/cureus.88144) shows how difficult diagnosis can be without clear criteria.

Arch’s ongoing Phase II trial for CS-AKI uses KDIGO to guide consistent diagnosis.

🔬 archbiopartners.com/our-science/lsaltpeptide

#AKI #CSAKI #KDIGO #NephSky

Frontiers | Chemotherapy-induced acute kidney injury: epidemiology, pathophysiology, and therapeutic approaches Despite significant advancements in oncology, conventional chemotherapy remains the primary treatment for diverse malignancies. Acute kidney injury (AKI) sta...

🧬 Frontiers in Nephrology (doi.org/10.3389/fneph.2024.1436896) examines chemotherapy-related AKI.

Arch is supporting an ongoing Phase II trial of cilastatin to prevent drug-induced AKI.

🔬 archbiopartners.com/our-science/cilastatin

#AKI #Cilastatin #NephSky #KidneyCare @frontiersin.bsky.social

November 5, 2025 - News Release Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia

🚨 Arch Biopartners has announced that the @fraserhealth.ca Research Ethics Board has approved Royal Columbian Hospital to join its Phase II trial of LSALT peptide to prevent CS-AKI.

📖 Latest News at www.archbiopartners.com/investor-hub/

#AKI #CSAKI #KidneyCare #NephSky

Attenuation of natural killer cell cytotoxicity by interaction between NKp30 of NK cells and dipeptidase 1 of colon cancer cells - Scientific Reports Scientific Reports - Attenuation of natural killer cell cytotoxicity by interaction between NKp30 of NK cells and dipeptidase 1 of colon cancer cells

🧬 @springernature.com - nature.com/articles/s41598-025-18475-z finds DPEP1 blocks NK-cell killing in colon cancer.

LSALT peptide is a DPEP1 inhibitor in a Phase II trial targeting CS-AKI. Approval would validate DPEP1 and open oncology exploration.

archbiopartners.com/our-science

#NephSky #DPEP1

Novo Nordisk Is Buying Biotech Akero Therapeutics. The Stock Soars. Novo Nordisk stock fell after it said it would buy Akero Therapeutics for $54 a share in cash, and an additional $6 if it gets U.S. approval of Efruxifermin, it’s treatment for fatty liver disease.

🚨 Novo Nordisk to acquire Akero Therapeutics in a $5.2B deal, expanding its MASH & metabolic portfolio with a Phase 3 FGF21 analogue @barrons.com: bit.ly/akero-novo-nordisk
Arch develops on-target drugs for AKI & CKD, a condition tied to metabolic dysfunction.
🔬 archbiopartners.com/about-us
#Biotech

Small Biotech Catapults 154% On A $2.1 Billion Novo Deal Novo Nordisk is licensing exclusive global rights to the company's experimental treatment for rare blood and kidney diseases.

🚨 Omeros jumps 154% after Novo Nordisk signs a $2.1B deal for Zaltenibart, now in testing for PNH and related kidney disorders.

@ibdinvestors.bsky.social:
bit.ly/omeros-novo-...

Arch Biopartners is developing on-target drugs for AKI and CKD.

🔬 archbiopartners.com/about-us

#Biotech #CKD #NephSky

Cisplatin Nephrotoxicity: Novel Insights Into Mechanisms and Preventative Strategies Cisplatin is a highly effective chemotherapeutic agent that has been used for more than 50 years for a variety of cancers; however, its use is limited by toxicity, including nephrotoxicity. In this in...

A 2023 review (www.seminarsinnephrology.org/article/S027... shows how cisplatin causes AKI through inflammation, oxidative stress, and cell injury.

Learn more about the Phase II trial evaluating cilastatin to protect kidneys.

🔬 archbiopartners.com/our-science/cilastatin

#AKI #Cilastatin #NephSky

📉 Kidney Medicine @kidneymed.bsky.social (Dec 2024): Cilastatin was linked to a 74% lower AKI risk in clinical trials, 46% in observational studies. Overall: 48%.

Arch is supporting the PONTiAK Phase II trial, now recruiting.

🔬 archbiopartners.com/our-science/cilastatin

#Cilastatin #AKI #NephSky

Frontiers | Global burden of chronic kidney disease due to diabetes mellitus, 1990-2021, and projections to 2050 IntroductionChronic kidney disease (CKD) is a serious complication of diabetes, and the global burden of the disease is gradually increasing.MethodsThis stud...

📚 @frontiersin.bsky.social 2025 (doi.org/10.3389/fendo.2025.1513008): CKD mortality due to diabetes has nearly tripled since 1990 and is projected to continue rising. Highlights need for on-target CKD treatments.

🔬 archbiopartners.com/our-science/ckd-platform

#CKD #KidneyCare #Nephsky

What’s behind the Mysterious Epidemic of Kidney Disease Killing Thousands of Young Men? As cases of chronic kidney disease emerge in outdoor laborers around the world, scientists are finding that repeated damage from prolonged extreme heat seems to be a leading factor to kidney failure

🌍 @sciam.bsky.social (bit.ly/sci-american...) highlights the global CKD burden and the need for better detection. Heat stress is one factor under study. Arch Biopartners has launched a CKD platform, complementing two Phase II AKI trials.

🔬 archbiopartners.com/our-science

#CKD #AKI #NephSky